You are here
Open
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
-
PAR-21-282: Blueprint Medtech: Small Business Translator (U44- Clinical Trial Optional)
Release Date: 08-20-2021Open Date: 09-20-2021 Due Dates: Multiple Close Date: 06-21-2024Blueprint MedTech The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). Innovators developing groundbreaking medical ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAR-24-098: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
Release Date: 01-22-2024Open Date: 02-22-2024 Due Dates: Multiple Close Date: 06-26-2026Background A biomarker is a defined characteristic that is measured as an indicator of a normal biological process, pathogenic process, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints. Because the measurement of the biomarker is integral to defining ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAS-22-196: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
Release Date: 06-21-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-08-2025Recommendations and milestones for Alzheimer's disease (AD) and AD-related dementias (ADRD) research from the National Alzheimer’s Project Act and the 2015, 2018, 2019, and 2021 Alzheimer's Disease Research Summits present a wide range of research and development proposals which, if pursued, have the potential to reduce the human burden and healthcare costs associated with AD/ADRD. As part of t ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
